These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27181031)

  • 1. Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science.
    Langley PC
    Curr Med Res Opin; 2016 Oct; 32(10):1641-1644. PubMed ID: 27181031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities.
    Langley PC
    Pharmacoeconomics; 1999 Sep; 16(3):211-24. PubMed ID: 10558036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of modeled pharmacoeconomic claims in formulary submissions.
    Langley PC
    J Med Econ; 2015; 18(12):993-9. PubMed ID: 26549802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology Assessment.
    Langley PC
    Innov Pharm; 2018; 9(3):1-5. PubMed ID: 34007719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
    Langley PC
    Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
    Anis AH; Gagnon Y
    Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockchains, Formulary Evaluations and Health Technology Assessment.
    Langley PC; Martin RE
    Innov Pharm; 2018; 9(4):. PubMed ID: 34007722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.
    Langley PC
    Innov Pharm; 2022; 13(3):. PubMed ID: 36627905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating pharmaceutical product claims: questions a formulary committee should ask.
    Schommer JC; Carlson AM; Rhee TG
    J Med Econ; 2015; 18(12):1000-6. PubMed ID: 26548326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment.
    Langley PC
    Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32668706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.
    Detsky AS
    Pharmacoeconomics; 1993 May; 3(5):354-61. PubMed ID: 10146886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using 'big data' to validate claims made in the pharmaceutical approval process.
    Wasser T; Haynes K; Barron J; Cziraky M
    J Med Econ; 2015; 18(12):1013-9. PubMed ID: 26548546
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.